Tag: RCT

INS 2022: Late-breaking research indicates safety of deep brain stimulation in...

Deep brain stimulation (DBS) offers a safe therapy option for reducing chorea in patients with Huntington’s disease, but it remains to be seen whether...

INS 2022: Occipital nerve stimulation shows clinical benefit and safety in...

A randomised controlled trial (RCT) presented at the International Neuromodulation Society (INS) congress (21–26 May 2022, Barcelona, Spain) has demonstrated significant and clinically relevant...

Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...

First patient implanted in clinical study assessing hypoglossal nerve stimulation for...

LivaNova has announced the first patient has been implanted as part of an investigational device exemption (IDE) clinical study, dubbed OSPREY (Treating obstructive sleep apnea using...

Nevro announces clinical data reinforcing significant and durable benefits of 10kHz...

Nevro Corporation has announced the results from data presentations at the 25th North American Neuromodulation Society (NANS) annual meeting (13–15 January 2022; Orlando, USA) supporting...
saint depression treatment

Novel neuromodulation technique could be “gamechanger” in treatment-resistant depression

Stanford accelerated intelligent neuromodulation therapy (SAINT)—a novel, high-dose intermittent theta-burst stimulation (iTBS)—was found to be safe and more effective than sham stimulation in a...
coating study phenox

ESMINT 2021: COATING study “badly needed” to assess surface modification of...

This year’s Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2021; 8–10 September, Nice, France and virtual) saw details of the...
crisp study scs

CRISP study indicates clinical benefit of non-paraesthesia-based approaches in burst SCS...

The CRISP (Comparison of paraesthesia mapping to anatomic midline-based burst programming strategies) study, published in Neuromodulation: Technology at the Neural Interface, has found that...
WE-TRUST study philips

Philips enrols first patient in WE-TRUST stroke study to assess new...

Royal Philips has announced that the first patient has been enrolled in the WE-TRUST (Workflow optimisation to reduce time to endovascular reperfusion for ultra-fast...

Stimwave launches post-market peripheral neuropathy pain relief randomised controlled trial

In honour of September Pain Awareness Month, Stimwave has announced the launch of a new randomised clinical trial treating painful peripheral neuropathy, known as...

Placebo-controlled RCTs of spinal cord stimulation are on the rise, but...

Important methodological aspects of clinical trials of spinal cord stimulation (SCS) using a placebo are consistently being poorly reported, says a recent systematic review....

SNIS 2019: Next-generation thrombectomy will be “even more powerful”

Matthew Gounis (Worcester, USA) talks to BLearning at SNIS 2019 (22–25 July, Miami, USA) about the current state of ischaemic stroke therapy. Gounis notes that...

Stimwave announces completion of enrolment for the Tsunami placebo-controlled double-blind randomised...

Stimwave has announced completion of patient enrolment and preliminary results of the first-of-its-kind Tsunami study. The Tsunami placebo-controlled double-blind randomised clinical trial (RCT) is...
Researchers at Ohio State University, USA, say deep brain stimulation from a device similar to a cardiac pacemaker can slow the decline of problem-solving and decision-making skills in Alzheimer’s patients.

Evoke: The first RCT to measure spinal cord activations in response...

The protocol design for a multicentre, prospective, randomised, double-blind study comparing ECAP- (evoked compound action potential) controlled closed-looped with open-loop, fixed output spinal cord...

Randomised trial of Penumbra 3D revascularisation device meets primary endpoints

The Penumbra 3D trial of the company’s 3D revascularisation device has successfully met the primary trial endpoints, demonstrating non-inferiority in both safety and efficacy...